Releases
BLRX
--
0.00%
--
  • All
  • Financials
  • Insiders
More
Webull provides the latest BioLine RX (BLRX) stock and general news. This information may help you make smarter investment decisions.
About BLRX
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.